Popular Filters
Trials for MZL Patients
Monoclonal Antibodies
Loncastuximab Tesirine for Marginal Zone Lymphoma
Recruiting1 awardPhase 2
Miami, Florida
This trial is testing a medication called loncastuximab tesirine in patients with immune cell cancers. The medication works by finding and sticking to cancer cells, then releasing a poison to kill them. Researchers want to see if this treatment is effective and safe for these patients. Loncastuximab tesirine is a recently approved treatment for a type of immune cell cancer that has returned or not responded to previous treatments.
Monoclonal Antibodies
Mosunetuzumab + Lenalidomide for Lymphoma
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a new treatment for lymphoma that involves using mosunetuzumab alone for four cycles, followed by an assessment of response. If the patient responds well, they will continue treatment with mosunetuzumab. If the patient does not respond well, they will receive mosunetuzumab with lenalidomide augmentation during the next four cycles.
Anti-tumor antibiotic
Tafasitamab + Lenalidomide + Rituximab for Follicular & Marginal Zone Lymphoma
Recruiting1 awardPhase 3
San Diego, California
This trial is testing if adding two drugs, tafasitamab and lenalidomide, to an existing treatment (rituximab) is more effective than just adding one drug (lenalidomide) for patients with certain types of lymphoma that have returned or not responded to treatment. The drugs aim to better target and destroy cancer cells while boosting the body's immune response against the cancer. Lenalidomide has shown activity in various lymphoma subtypes, including diffuse large B-cell lymphoma, and is often combined with rituximab for enhanced efficacy.
Trials for Follicular Lymphoma Patients
Odronextamab + Lenalidomide for Lymphoma
Recruiting2 awardsPhase 3
Waukesha, Wisconsin
This trial is studying an experimental drug to see if it is safe and effective in treating NHL with FL and MZL that has come back or not responded to treatment. It will compare the drug to current standard-of-care treatment.
Monoclonal Antibodies
Mosunetuzumab + Lenalidomide for Lymphoma
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a new treatment for lymphoma that involves using mosunetuzumab alone for four cycles, followed by an assessment of response. If the patient responds well, they will continue treatment with mosunetuzumab. If the patient does not respond well, they will receive mosunetuzumab with lenalidomide augmentation during the next four cycles.
Anti-tumor antibiotic
Tafasitamab + Lenalidomide + Rituximab for Follicular & Marginal Zone Lymphoma
Recruiting1 awardPhase 3
San Diego, California
This trial is testing if adding two drugs, tafasitamab and lenalidomide, to an existing treatment (rituximab) is more effective than just adding one drug (lenalidomide) for patients with certain types of lymphoma that have returned or not responded to treatment. The drugs aim to better target and destroy cancer cells while boosting the body's immune response against the cancer. Lenalidomide has shown activity in various lymphoma subtypes, including diffuse large B-cell lymphoma, and is often combined with rituximab for enhanced efficacy.
Trials With No Placebo
Odronextamab + Lenalidomide for Lymphoma
Recruiting2 awardsPhase 3
Waukesha, Wisconsin
This trial is studying an experimental drug to see if it is safe and effective in treating NHL with FL and MZL that has come back or not responded to treatment. It will compare the drug to current standard-of-care treatment.
Monoclonal Antibodies
Loncastuximab Tesirine for Marginal Zone Lymphoma
Recruiting1 awardPhase 2
Miami, Florida
This trial is testing a medication called loncastuximab tesirine in patients with immune cell cancers. The medication works by finding and sticking to cancer cells, then releasing a poison to kill them. Researchers want to see if this treatment is effective and safe for these patients. Loncastuximab tesirine is a recently approved treatment for a type of immune cell cancer that has returned or not responded to previous treatments.
Monoclonal Antibodies
Mosunetuzumab + Lenalidomide for Lymphoma
Recruiting1 awardPhase 2
New Haven, Connecticut
This trial is testing a new treatment for lymphoma that involves using mosunetuzumab alone for four cycles, followed by an assessment of response. If the patient responds well, they will continue treatment with mosunetuzumab. If the patient does not respond well, they will receive mosunetuzumab with lenalidomide augmentation during the next four cycles.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.